The integration of artificial intelligence (AI) into healthcare is here to stay, and adoption is accelerating.
Analysts are projecting that by 2035 the gross value added by AI to the healthcare industry will be $461 billion on top of a baseline $2.26 trillion.
Behind the scenes, several new AI healthcare tech developments are taking place, with updates recently coming from Avant Technologies, Inc., Tempus AI, Inc., Tevogen Bio Holdings Inc., GE HealthCare Technologies Inc., and Schrödinger, Inc.
At the regulatory level, the World Health Organization (WHO) recently announced a major global initiative to set unified standards for AI in healthcare, the US Food and Drug Administration (FDA) is working to catch up on approving new AI tech in the sector, with the latest being a cardioverter defibrillator.
As AI continues to evolve from concept to clinical application, these companies are quietly shaping the future of medicine at the infrastructure level. With regulatory momentum building and real-world deployments expanding, investors may want to pay attention as this shift begins to accelerate.
【MORE】